Medicinsk godkendt artikel
Vyepti is used as a preventive treatment for migraines.
Vyepti is given as an infusion. Vyepti has been developed specifically to prevent migraines and is approved for adults who have at least 4 seizures a month.
It is known that CGRP (calcitonin gene-related peptide), which is formed in our nervous system, plays an active role in a migraine attack.
Vyepti works by binding specifically to and blocking the activity of the CGRP molecule in the brain. This can decrease the number and strength of your migraine attacks.
Since Vyepti is given directly into the bloodstream, the maximum concentration in the blood is reached already after 30 min.
Vyepti has a half-life of about 27 days.
Irritation of the respiratory tract, fatigue and rarely allergic reaction such as difficulty breathing, weak pulse, drop in blood pressure, itching and/or swelling of the lips and tongue. Since Vyepti has a stricter reporting obligation, it is important that you tell your doctor if you experience any side effects other than those described.
You should not be treated with Vyepti if you have certain forms of cardiovascular disease.
Vyepti must not be used by pregnant women and breast-feeding mothers.
You must stop taking Vyepti at least 5 months before you try to become pregnant.
Checked blood pressure.
Usually 100 mg of Vyepti mixed with 100 ml of saline is given each time. If necessary, the dose may be gradually increased to a maximum of 300 mg i.v. every 12. Week.
Treatment takes place in the clinic every 12 weeks. Vyepti is given intravenously, which means by drip and further through a small needle placed in a vein, typically in the back of the hand or in the elbow bend. The infusion itself is given over half an hour, after which it is rinsed with 50 ml of saline.
You can go home immediately after the end of treatment.
